DK2079735T3 - N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl-(1-(thiazol-4-ylmethyl)-piperidin-4-yliden)-methyl)-benzamid, fremgangsmåde til fremstilling heraf samt anvendelse heraf til behandling af smerter, angst og depression - Google Patents

N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl-(1-(thiazol-4-ylmethyl)-piperidin-4-yliden)-methyl)-benzamid, fremgangsmåde til fremstilling heraf samt anvendelse heraf til behandling af smerter, angst og depression

Info

Publication number
DK2079735T3
DK2079735T3 DK07835125.1T DK07835125T DK2079735T3 DK 2079735 T3 DK2079735 T3 DK 2079735T3 DK 07835125 T DK07835125 T DK 07835125T DK 2079735 T3 DK2079735 T3 DK 2079735T3
Authority
DK
Denmark
Prior art keywords
methyl
ylidene
quinolin
thiazol
benzamide
Prior art date
Application number
DK07835125.1T
Other languages
Danish (da)
English (en)
Inventor
Khanh Bui
Cathy Dantzman
Glen Ernst
Valerie Hoesch
Thomas Hudzik
Megan Murphy King
Jie Liu
Jingbo Yan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK2079735T3 publication Critical patent/DK2079735T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK07835125.1T 2006-10-20 2007-10-19 N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl-(1-(thiazol-4-ylmethyl)-piperidin-4-yliden)-methyl)-benzamid, fremgangsmåde til fremstilling heraf samt anvendelse heraf til behandling af smerter, angst og depression DK2079735T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20
PCT/SE2007/000924 WO2008048171A1 (en) 2006-10-20 2007-10-19 N- (2 -hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression.

Publications (1)

Publication Number Publication Date
DK2079735T3 true DK2079735T3 (da) 2012-05-21

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07835125.1T DK2079735T3 (da) 2006-10-20 2007-10-19 N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl-(1-(thiazol-4-ylmethyl)-piperidin-4-yliden)-methyl)-benzamid, fremgangsmåde til fremstilling heraf samt anvendelse heraf til behandling af smerter, angst og depression

Country Status (32)

Country Link
US (2) US7659286B2 (OSRAM)
EP (1) EP2079735B1 (OSRAM)
JP (1) JP4668346B2 (OSRAM)
KR (1) KR20090065534A (OSRAM)
CN (1) CN101528739B (OSRAM)
AR (1) AR063345A1 (OSRAM)
AT (1) ATE543818T1 (OSRAM)
AU (2) AU2007313515B2 (OSRAM)
BR (1) BRPI0717631A2 (OSRAM)
CA (1) CA2667041C (OSRAM)
CL (1) CL2007003009A1 (OSRAM)
CO (1) CO6180450A2 (OSRAM)
CY (1) CY1112718T1 (OSRAM)
DK (1) DK2079735T3 (OSRAM)
ES (1) ES2379519T3 (OSRAM)
HR (1) HRP20120344T1 (OSRAM)
IL (1) IL197876A0 (OSRAM)
MX (1) MX2009003974A (OSRAM)
MY (1) MY148880A (OSRAM)
NO (1) NO20091969L (OSRAM)
NZ (1) NZ577060A (OSRAM)
PE (2) PE20080892A1 (OSRAM)
PL (1) PL2079735T3 (OSRAM)
PT (1) PT2079735E (OSRAM)
RS (1) RS52260B (OSRAM)
RU (1) RU2454414C2 (OSRAM)
SA (1) SA07280549B1 (OSRAM)
SI (1) SI2079735T1 (OSRAM)
TW (1) TW200826939A (OSRAM)
UA (1) UA97648C2 (OSRAM)
UY (1) UY30652A1 (OSRAM)
WO (1) WO2008048171A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060010811A (ko) * 2003-05-16 2006-02-02 아스트라제네카 아베 디아릴메틸리덴 피페리딘 유도체, 그의 제조 및 그의 용도
MY148880A (en) * 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
JP2011520956A (ja) * 2008-05-20 2011-07-21 アストラゼネカ・アクチエボラーグ 不安大うつ病性障害を処置する方法
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
DK3233825T3 (da) * 2014-12-19 2020-06-29 Pharmnovo Ab Diarylmethylidenpiperidinderivater og deres anvendelse som deltaopioidreceptoragonister
US11286728B2 (en) 2018-09-21 2022-03-29 Postle Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
DK1049676T3 (da) * 1997-12-24 2006-01-16 Ortho Mcneil Pharm Inc 4-[Aryl(piperidin-4-yl)]aminobenzamider, som binder til delta-opioidreceptoren
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
EP1242398A2 (en) 1999-12-20 2002-09-25 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6552036B2 (en) 2000-03-03 2003-04-22 Ortho-Mcneil Pharmaceutical, Inc. 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
KR20060010811A (ko) 2003-05-16 2006-02-02 아스트라제네카 아베 디아릴메틸리덴 피페리딘 유도체, 그의 제조 및 그의 용도
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301441D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
PE20140634A1 (es) 2014-06-19
PL2079735T3 (pl) 2012-07-31
CO6180450A2 (es) 2010-07-19
NZ577060A (en) 2011-01-28
ES2379519T3 (es) 2012-04-26
AR063345A1 (es) 2009-01-21
CN101528739A (zh) 2009-09-09
CA2667041C (en) 2011-09-06
AU2007313515B2 (en) 2010-11-25
AU2010226996A1 (en) 2010-10-28
MX2009003974A (es) 2009-04-27
RS52260B (sr) 2012-10-31
TW200826939A (en) 2008-07-01
EP2079735A1 (en) 2009-07-22
PE20080892A1 (es) 2008-09-11
WO2008048171A1 (en) 2008-04-24
JP2010506910A (ja) 2010-03-04
US7659286B2 (en) 2010-02-09
HK1131556A1 (en) 2010-01-29
JP4668346B2 (ja) 2011-04-13
HRP20120344T1 (hr) 2012-05-31
UY30652A1 (es) 2008-05-31
US20080182875A1 (en) 2008-07-31
IL197876A0 (en) 2009-12-24
SA07280549B1 (ar) 2010-09-29
MY148880A (en) 2013-06-14
PT2079735E (pt) 2012-05-07
UA97648C2 (ru) 2012-03-12
KR20090065534A (ko) 2009-06-22
CY1112718T1 (el) 2016-02-10
CL2007003009A1 (es) 2008-06-06
CN101528739B (zh) 2011-11-30
EP2079735B1 (en) 2012-02-01
EP2079735A4 (en) 2010-12-29
US7977355B2 (en) 2011-07-12
CA2667041A1 (en) 2008-04-24
ATE543818T1 (de) 2012-02-15
AU2007313515A1 (en) 2008-04-24
US20100160374A1 (en) 2010-06-24
NO20091969L (no) 2009-05-20
RU2009111337A (ru) 2010-11-27
RU2454414C2 (ru) 2012-06-27
SI2079735T1 (sl) 2012-05-31
BRPI0717631A2 (pt) 2013-10-29

Similar Documents

Publication Publication Date Title
DK1755743T3 (da) Beta-hydroxybutyrat og derivater til behandling af depression og angst
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
SI2182949T1 (sl) (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciklo(2.2.2)okt-3-il)benzofuran -2-karboksamid, nove oblike soli in postopki za njihovo uporabo
DK2079735T3 (da) N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl-(1-(thiazol-4-ylmethyl)-piperidin-4-yliden)-methyl)-benzamid, fremgangsmåde til fremstilling heraf samt anvendelse heraf til behandling af smerter, angst og depression
DK1812110T3 (da) Apparat til behandling af dermatologiske lidelser
DK2120604T3 (da) Fremgangsmåde til fraktionering af havre, produkter derved opnået, og anvendelser deraf
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
DK2176214T3 (da) Ny fremgangsmåde til syntese af (7-methoxy-1-naphthyl)acetonitril og anvendelse heraf ved syntese af agomelatin
EP2221145A4 (en) BALL BEAM AND BALL BEAM PROCESSING METHOD
DK1802749T3 (da) KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser
DK2763981T3 (da) Fremgangsmåde til fremstilling af 1-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-on-hydrochlorid og mellemprodukter anvendt deri
DK1564203T3 (da) Ny fremgangsmåde til fremstilling af (7-methoxy-1-napthyl)acetonitril og anvendelse heraf til syntese af agomelatin
DK1750700T3 (da) Veterinærmedicinsk væskepræparat, fremgangsmåde til fremstilling af dette samt anvendelse deraf
DE602005025710D1 (de) Flüssigkeits-Abstreifvorrichtung
DK2044099T3 (da) Fremgangsmåde til fremstillingen af s-fluormethyl-6,9-difluor-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-dien-17-carbothiat og mellemprodukter
BRPI0914167A2 (pt) formas sólidas de (1r,2s,3r)-1-(2-(isoxa-zol-3-il)-1h-imidazol-4il) butano-1,2,3,4-tetraol e métodos de uso das mesmas
DK1564204T3 (da) Ny fremgangsmåde til fremstilling af (7-methoxy-3,4-dihydro-1-naphthalenyl) acetonitril og anvendelse heraf ved syntese af agomelatin
DK1771415T3 (da) 2-(1H-indolylsulfanyl)-arylaminderivater til anvendelse i behandlingen af affektive sygdomme, smerte, ADHD og stressinkontinens
WO2008071870A3 (fr) Utilisation de l ' agomelatine pour le traitement du syndrome de smith magenis
DK1564205T3 (da) Fremgangsmåde til fremstilling af (7-methoxy-1-naphthyl)-acetonitril og anvendelse heraf ved syntese af agomelatin
ITRM20050478A1 (it) Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia.
WO2008071869A3 (fr) Utilisation de l'agomelatine pour le traitement de la leucomalacie periventriculaire
ITCR20050017A1 (it) Impianto per osteosintesi del gomito e relativo applicatore
DK1714647T3 (da) Anvendelse af agomelatin til fremstilling af et lægemiddel til behandling af bipolære sygdomme
PT2117533E (pt) Composição farmacêutica à base de stachytarpheta sp., processo para a sua obtenção e sua utilização no tratamento de vitiligo